ASCIA Submissions 2019

  • ASCIA opening statement to the public hearing in Sydney on 19 November 2019 for the Parliamentary Inquiry into Allergies and Anaphylaxis. pdfASCIA opening statement parliamentary inquiry 19-11-19 

  • ASCIA submission to the Parliamentary Inquiry into Allergies and Anaphylaxis. Submitted 24 October 2019.
    pdfASCIA Submission Parliamentary Inquiry 24-10-19 or on the government website at Submission 153. The Inquiry report was tabled on 15 June 2020 in the Parliament of the Commonwealth of Australia.  pdfWalking the allergy tightrope1.15 MB 

  • ASCIA response to National Blood Authority (NBA) request for information regarding Berinert. Submitted 4 September 2019.
    pdfASCIA letter NBA Berinert 20190904359.77 KB

  • Feedback to Australian National Breastfeeding Strategy. Submitted 5 August 2019, further to submissions on 30 November 2018 and 18 June 2018. pdfASCIA response Australian National Breast Feeding Strategy 20190805203.32 KB This request was successful.

  • ASCIA application to the Medical Services Advisory Committee (MSAC) for a food allergen challenge Medical Benefits Schedule (MBS) item number. Submitted 18 July 2019. This submission was unsuccessful.

  •  ASCIA submission to Consultation on the Draft National Clinical Quality Registry Strategy. Submitted 20 June 2019.

  • ASCIA submission to the Food Standards Australia New Zealand (FSANZ) Review of Food Standards Code chapter 3 and 4 – Food Safety Management Requirements (Australia only). Submitted 14 June 2019.
    pdfASCIA submission FSANZ 14-06-201989.03 KB

  • ASCIA response to Pharmaceutical Benefits Advisory Committee (PBAC) request for information regarding Dupilumab. Submitted 30 May 2019.  pdfASCIA letter PBAC Dupilumab 20190530172.30 KB  This submission was unsuccessful, but Dupilumab has since been recommended by the PBAC for PBS listing. For details refer to the announcement here.

  •  ASCIA letter to National Blood Authority (NBA) regarding BloodSTAR issues. Submitted 27 May 2019. pdfASCIA letter NBA BloodSTAR 20190527 152.92 KB  The NBA has responded and will follow up on the issues raised in the ASCIA letter.

  • ASCIA response to new Medicare Benefits Schedule (MBS) Review Specialist and Consultant Physician Consultation Clinical Committee of the MBS Review Taskforce. Submitted 25 March 2019. 

  • ASCIA letter to the Royal Australasian College of Physicians (RACP) President requesting Therapeutic Goods Authority (TGA) Authorised Prescriber (AP) endorsements. Submitted 28 February 2019.  pdfASCIA letter RACP President 2019022876.31 KB  This request was unsuccessful, however the TGA has since changed the AP process.

  • ASCIA letter to the TGA regarding BICOM. Submitted 17 January 2019. pdfASCIA letter TGA BICOM 2019-01-1749.04 KB


Mod ASCIA Member
Donate to AIFA
go to NAC website

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia